Accuracy of Ultrasound Exam, Including Doppler and Elastography, in the Diagnosis of VOD, Following Bone Marrow Transplantation
NCT ID: NCT04660266
Last Updated: 2020-12-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
200 participants
INTERVENTIONAL
2020-12-31
2022-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Validation of the use of intentional ultrasound examination, which includes Doppler and elastography for the diagnosis of obstructive venous disease of the liver within 21 days after bone marrow transplantation.
Protocol:
Patients who are planned for a bone marrow transplantaion will be recruited for the study by the staff of the Transplant Department. Inclusion criteria: Patients over the age of 18 before a bone marrow transplantation.
Eligibility criteria: Transplanted under 18 years of age
Research protocol:
After informed consent, patients will undergo an ultrasound examination before the transplant.
After 14 days and again after 21 days patients will undergo two more US exams, If there is a change in their clinical condition the patients will undergo additional examination accordingly.
At the same time on the 14th and 21st day a clinical evaluation will be performed by the clinical physician in the transplant department based on clinical criteria of European Blood and Brain Transplant Association (EBMT).
The results of the clinical evaluation and blood test results will be collected.
Patients will be divided into two groups:
* Control group: Patients who did not develop VOD( veno occlusive disease ) during 21 days.
* Study group: Patients who developed VOD during 21 days.
All ultrasound examination data will be compared between the two groups in
In addition will be collected:
* Demographics - age, sex.
* Background diseases including heart and liver diseases.
* Basic disease as a transplantation cause.
All data will be collected anonymously and coded separately.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Validation of the use of intentional ultrasound examination, which includes Doppler and elastography for the diagnosis of obstructive venous disease of the liver within 21 days after bone marrow transplantation.
Protocol:
Patients who are planned for a bone marrow transplantaion will be recruited for the study by the staff of the Transplant Department. Inclusion criteria: Patients over the age of 18 before a bone marrow transplantation.
Eligibility criteria: Transplanted under 18 years of age
Research protocol:
After informed consent, patients will undergo an ultrasound examination before the transplant.
The test will include:
1. Demonstration of liver including its size.
2. Gallbladder demonstration including its width and wall thickness.
3. Main portal vein width, Speed and flow direction in main portal vein.
4. Evaluation of umbilical vein in the falciform ligament to check existence of flow and venous width in case it opened.
5. Assessment of existence a small / medium or large amount of ascites measurement of resistance index in the main hepatic artery.
6. Complete elastography examination.
After 14 days and again after 21 days patients will undergo two more US exams, If there is a change in their clinical condition the patients will undergo additional examination accordingly.
At the same time on the 14th and 21st day a clinical evaluation will be performed by the clinical physician in the transplant department based on clinical criteria of European Blood and Brain Transplant Association (EBMT).
The results of the clinical evaluation and blood test results will be collected.
Patients will be divided into two groups:
* Control group: Patients who did not develop VOD( veno occlusive disease ) during 21 days.
* Study group: Patients who developed VOD during 21 days.
All ultrasound examination data will be compared between the two groups in
In addition will be collected:
* Demographics - age, sex.
* Background diseases including heart and liver diseases.
* Basic disease as a transplantation cause.
All data will be collected anonymously and coded separately.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
all cohort
Liver Ultrasound
liver ultrasound examination, including gray-scale and seven Doppler examination
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Liver Ultrasound
liver ultrasound examination, including gray-scale and seven Doppler examination
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rambam Health Care Campus
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rambam Medical Center
Haifa, Israek, Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
NIRA BECK-RAZI, md
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Related Info
Related Info
Related Info
Related Info
Related Info
Related Info
Related Info
Related Info
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0696-20-RMB
Identifier Type: -
Identifier Source: org_study_id